Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function
Authors:
- Roberto GuercioliniRGRoberto Guerciolini
- Paul J. WilliamsPWPaul J. Williams
- 1 January 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (3) , 390-398
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary SyndromesCirculation, 2002
- Long-term Efficacy of Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent InterventionJAMA, 2002
- Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent InterventionJAMA, 2001
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- Statistical Graphics in Pharmacokinetics and Pharmacodynamics: A TutorialAnnals of Pharmacotherapy, 1998
- Effect of Ca 2+ on GP IIb-IIIa Interactions With IntegrilinCirculation, 1997
- Population Pharmacokinetic Modeling: The Importance of Informative GraphicsPharmaceutical Research, 1995
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976